Gary Clark: Unfiltered

The European Commission has approved Insmed’s BRINSUPRI, the first targeted therapy for non-cystic fibrosis bronchiectasis in the EU. This marks a significant step forward for the 600,000+ affected Europeans.

RespireRx Pharmaceuticals seeks a $45 million lifeline to advance neurological treatments, but a history of financial issues and delayed filings raise questions about the company's viability. A deep dive into its programs and funding strategy.

Following an SEC order revoking its stock registration, RespireRx Pharmaceuticals aims to regain compliance and advance its neurological disorder pipeline, though financial health remains a significant hurdle.

Apyx Medical Corporation secures $10 million in a public offering, bolstering its position in the expanding surgical aesthetics market and funding continued innovation in its Helium Plasma Technology platform.

Biopharmaceutical firm MediciNova appoints Dr. Christopher Breder as Clinical and Regulatory Advisor, bolstering its pipeline amidst growing competition and complexity in neurodegenerative disease treatment.

Biotech firm Invivyd secures $125 million to advance its VYD2311 antibody, targeting evolving COVID-19 variants and offering potential solutions for Long COVID. Is this funding a sign of confidence or a risky bet?

Fennec Pharmaceuticals secured $40.25 million in a public offering to advance its lead product, PEDMARK, which aims to reduce ototoxicity in cancer patients. The funding will also address debt and bolster working capital.

Apyx Medical Corporation announced a planned stock offering as it capitalizes on rising demand for minimally invasive body contouring procedures. The company’s recent financial performance and strategic expansion plans support the move.

Biopharma firm Invivyd secured $125 million in a public offering, fueling commercialization of its novel antibody, VYD2311, and expansion into RSV and measles treatments. Analysts question if the funding is enough.

A new research collaboration backed by a $7 million NIH grant aims to accelerate the development of novel antifungal therapies, including Scynexis’ next-generation ‘fungerps,’ to address a growing global health crisis.

Five-year results from a Phase 2 trial show durable responses with REZLIDHIA in relapsed/refractory AML patients, even those previously treated with venetoclax. The data signals potential for expanded use and market growth.

Solid Biosciences’ licensing deal with Andelyn Biosciences signals a shift in gene therapy manufacturing – outsourcing critical components for broader access and accelerated development. A new business model emerges.

Biotech firm Angiex Inc. has raised $31 million to support Phase 1 trials of AGX101, a first-in-class antibody-drug conjugate designed to deliver cancer-killing drugs directly into tumor cell nuclei, offering a potentially more effective and targeted treatment.

Silo Pharma partners with Allucent to advance a novel PTSD treatment while doubling down on a controversial cryptocurrency treasury strategy. Can this biopharmaceutical firm navigate both innovative science and volatile digital assets?

Biotech firm Acumen Pharmaceuticals begins a long-term extension of its Phase 2 Alzheimer’s trial, focusing on a novel approach to combatting the disease by targeting soluble amyloid beta oligomers. Is this a turning point for Alzheimer's treatment?

The FDA has accepted a supplemental application for Arcutis Biotherapeutics’ ZORYVE cream, potentially offering the first-ever topical treatment for plaque psoriasis in children as young as 2 years old, addressing a significant gap in care.

TGS launches a major 3D seismic survey in Brazil's Pelotas Basin, signaling growing interest in this underexplored region with significant oil potential. Advanced tech de-risks future exploration.